02/17/11Uppsala Sweden -- The Swedish dental company Doxa has signed an exclusive global distribution contract for Ceramir Crown & Bridge dental cement with Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of health care products and services to office-based practitioners.
“We are very pleased to have the dental market leader Henry Schein representing Ceramir Crown & Bridge exclusively around the world. Henry Schein has a proven track record for communicating the unique benefits of technology-driven products in markets around the world, and we look forward to building our share of market with them as our partner,” said Doxa’s CEO, Fredrik Alpsten.
Ceramir Crown & Bridge represents the next generation of dental cements,” said Carey Lyons, President of Henry Schein’s Exclusive Brands Group. “It is bioceramic with a nanostructure that essentially allows it to integrate with the tooth and thus minimizes the risk for micro-leakage and sensitivity. We are excited to add the Doxa product to the growing list of global exclusives that we offer our customers as part of our commitment to enhance the success of their practices and provide the very best patient care.”
In May 2010 Ceramir Crown & Bridge received Frost & Sullivan’s “New Product Innovation Award.” The following statement was delivered when the award was presented: “For revolutionizing the dental cements industry, Doxa is the worthy recipient of the 2010 European Frost & Sullivan Award for New Product Innovation of the Year.”
Ceramir Crown & Bridge has quickly become very popular among dentists, since it is easy to work within the mouth’s natural wet environment. Dentists and users unanimously report less postoperative sensitivity after cementing. Doxa also believes that there is less risk for treatments failing over time. In Sweden, recementing constitutes about 15 percent of all cement treatments, due to problems such as loosening of a crown or veneers. In total such recementing procedures amount to around 70,000 per year.
“The dental cement market in the western world is estimated to be approximately 10 billion SEK and is expected to grow by 6-8 percent annually. In this market Ceramir Crown & Bridge is unique of its kind,” says Fredrik Alpsten.
Doxa will continue to build a support infrastructure in the US and Europe in order to provide marketing support to Henry Schein.
In November 2010 Doxa’s patent for the compound comprising the foundation of Ceramir Crown & Bridge was approved in both Europe and the United States. Doxa has 80 approved patents within 22 different patent categories.
Ceramir Crown & Bridge is the first in a series of planned bioceramic dental products from Doxa based on the same technology.
For additional information, please contact:
Fredrik Alpsten, President/CEO of Doxa AB, phone +46 18 478 2060, cell: +46 70 667 3106.
About Ceramir Crown & Bridge:
Ceramir Crown & Bridge is a dental cement intended for conventional prosthetics. Ceramir Crown & Bridge is easy to use and has stable sealing abilities for the treated tooth. It also has good retention properties and is gentle on both human tissue and the environment. Ceramir Crown & Bridge is self-hardening, and no drying or preparation processes are necessary.
For more information, visit the Ceramir Web site at www.ceramir.se
Doxa is a Swedish dental company that markets sells and develops bioceramic dental products. The company´s largest shareholders are majority owner SLS Invest AB, Omega Fund, BGA Capital AB, Länsförsäkringsbolagen as well as the founder, Leif Hermansson. There are approximately 1,300 additional shareholders.
For more information, visit the Doxa Web site at www.doxa.se
About Henry Schein:
Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of health care products and services to office-based practitioners, is a Fortune 500® company and a member of the NASDAQ 100® Index.
The Company is recognized for its excellent customer service and highly competitive prices. Henry Schein’s The Company's five businesses – North American Dental, North American Medical, North American Animal Health, International and Technology – serve more than 700,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.
Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.
Headquartered in Melville, N.Y., Henry Schein employs more than 14,000 people and has operations or affiliates in 24 countries. The Company's net sales reached a record $6.5 billion in 2009.
For more information, visit the Henry Schein Web site at www.henryschein.com.